Last reviewed · How we verify

NCT03292848

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

Completed Phase 1 Last updated 12 June 2018
What this trial tests

Phase 1 trial testing Brexpiprazole in ADHD in 24 participants. Completed in 21 May 2018.

Timeline
10 October 2017
Primary endpoint
21 May 2018
21 May 2018

Quick facts

Lead sponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment24
Start date10 October 2017
Primary completion21 May 2018
Estimated completion21 May 2018
Sites9 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. — full company profile →

Who can join

Adults 6 to 12, any sex, with ADHD or Autism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to assess pharmacokinetics, safety and tolerability of brexpiprazole in children ages 6 to \<13 years with CNS disorders.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?
    Gładysz D, Krzywdzińska A, Hozyasz KK. · · 2018 · cited 77× · PMID 29307081 · DOI 10.1007/s12035-017-0822-x

Verify or expand the search:

Other trials of Brexpiprazole

Trials testing the same drug.

Other recruiting trials for ADHD

Currently open trials in the same condition.

Other Otsuka Pharmaceutical Development & Commercialization, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03292848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing